(Q33385353)

English

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Corinne Haioun

3

0 references

author name string

Vincent Ribrag

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christian Gisselbrecht

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gilles Salles

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean-Baptiste Golfier

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marjan Ertault

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christophe Ferme

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Josette Briere

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pauline Brice

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nicolas Mounier

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4540-4546

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of phase II clinical trials in haematology and oncology: comparison of the triangular test to the usual methods.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24518

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24518

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33385353&oldid=1624405180"